Go Symbol Lookup
Loading...

Rich & Richer: Jewel Of The Luxury Crown

 Text Size  
Published: Thursday, 3 May 2007 | 9:26 AM ET
By: By CNBC.com Staff

It's easy to spend a fortune on jewelry -- one piece at a time.

These days, items costing $20,000 and up are the fastest growing category of jewlery for Cartier, Tiffany & Co. and Bulgari. And suddenly the hottest market in the luxury business is the U.S.

Rich & Richer
A look at one of the fastest growing categories in retail, with CNBC's Margaret Brennan

As Margaret Brennan reports, Italy's Bulgari has targeted the U.S. for aggressive expansion. The U.S. already accounts for 30% of the company's sales, but the Rome-based company just refurbished its flagship New York City store and plans additional stores. The company is also considering expanding into malls and high-end department stores.

Richemont's Cartier and U.S.-based Tiffany are also expanding. Tiffany, for instance, plans five to seven stores in the Midwest -- all 5,000 square feet.

Saks is looking to create branded jewelry, working with the likes of Chanel and Gucci to compete in the lucrative market.

 Print
Suddenly, the U.S. is the lap of luxury and Bulgari, Tiffany and Cartier are all looking to expand here.
  Price   Change %Change
TIF ---
SKS ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured

U.S. Video

  • Discussing the state of Detroit's economy, with CNBC Contributor Keith Boykin; Heather Higgins, Independent Women's Voice; and Doug Holtz-Eakin, American Action Forum.

  • Larry Kudlow discusses the journalistic merit of a Financial Times article, which triggered a brief sell-off in U.S markets. Larry McDonald, Newedge; Ed Butowsky, Chapwood Investments; and Ron Kruszewski, Stifel Nicolaus join in the discussion later.

  • The Supreme Court ruled today that the FTC can keep challenging "pay to delay" deals between pharmaceutical companies and generic drugmakers. CNBC Contributor Keith Boykin; Heather Higgins, Independent Women's Voice; and Doug Holtz-Eakin, American Action Forum, discuss.